PT Kalbe Farma Tbk 2012 AR2
The report highlights PT Kalbe Farma Tbk.'s solid performance in 2012, achieving a 25.0% increase in net sales to Rp13,636 billion and a 17.0% growth in net income to Rp1,734 billion. The company expanded its manufacturing and distribution capacities, including the inauguration of a new generic drug facility and the acquisition of PT Hale International. Kalbe also advanced its sustainability initiatives under the 'Kalbe Berbagi' program, engaging over 2,350 employee volunteers and benefiting over 100,000 individuals in health, education, and environmental projects.
Company: PT Kalbe Farma Tbk
Sector: Health Care
Country: Indonesia
Year: 2012
Type: AR2
Pages: 392
Back to company
PT Kalbe Farma Tbk
Annual Report
The report highlights PT Kalbe Farma Tbk.'s solid performance in 2012, achieving a 25.0% increase in net sales to Rp13,636 billion and a 17.0% growth in net income to Rp1,734 billion. The company expanded its manufacturing and distribution capacities, including the inauguration of a new generic drug facility and the acquisition of PT Hale International. Kalbe also advanced its sustainability initiatives under the 'Kalbe Berbagi' program, engaging over 2,350 employee volunteers and benefiting over 100,000 individuals in health, education, and environmental projects.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English, Indonesian
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees